Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction

Internal Medicine

Volumn 43, Issue 11, 2004, Pages 1015-1022

  Katayama, Toshiro ^a,b   Nakashima, Hiroshi ^b   Furudono, Shinnosuke ^b   Honda, Yukiharu ^b   Suzuki, Shin ^b   Yano, Katsusuke ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; Adrenomedullin; Neurohumoral activation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ADRENOMEDULLIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE DERIVATIVE; HEPARIN; LIDOCAINE; LOSARTAN; NEUROHORMONE; NICORANDIL; NORADRENALIN; QUINAPRIL; RENIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY STENT; ELECTROCARDIOGRAPHY; FEMALE; HEART DEATH; HEART FAILURE; HEART FUNCTION TEST; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CATECHOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDES; PROGNOSIS; RISK FACTORS;

EID: 10244225336     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.1015     Document Type: Article

References (30)

1. Rauleau JL, de Champlain J, Klein M, et al. Activation of neurohumoral systems in post-infarction left ventricular dysfunction. J Am Coll Cardiol 22: 390-398, 1993.
2. Vaughan DE, Lamas GA, Pfeffer MA. Role of ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 66: 529-532, 1990.
3. McAlpine HM, Cobbe SM. Neuro-endocrine changes in acute myocardial infarction. Am J Med 84: 61-66, 1988.
4. Michorowski B, Ceremuzynski L. The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J 4: 259-264, 1983.
5. Yoshitomi Y, Nishikimi T, Kojima S, et al. Plasma levels of adrenomedullin in patients with acute myocardial infarction. Clin Sci 94: 135-139, 1998.
6. Miyao Y, Nishikimi T, Goto Y, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 79: 39-44, 1998.
7. Kobayashi K, Kitamura K, Hirayama N, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 131: 676-680, 1996.
8. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88: 82-91, 1993.
9. Inoue T, Sakuma M, Yaguchi I, et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left-ventricular function after acute myocardial infarction. Am Heart J 143: 790-796, 2002.
10. Sigurdsson A, Held P, Swedberg K. Short-and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126: 1068-1076, 1993.
11. Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hyperten Res 26: S121-S127, 2003.
12. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203, 1994.
13. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
14. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95: 46-54, 1995.
15. Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol 19: S51-S58, 1992.
16. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19: 1552-1563, 1998.
17. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 24: 583-591, 1994.
18. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93: 1963-1969, 1996.
19. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412, 1991.
20. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469, 1993.
21. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immuno-reactive adrenomedullin in human tissue and plasma. FEBS Lett 338: 6-10, 1994.
22. Hirata Y, Hayakawa H, Suzuki Y, et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension 25 790-795, 1995.
23. Lippton H, Chang JK, Hao Q, Summer W, Hyman AL. Adrenomedullin dilates the pulmonary vascular bed in vivo. J Appl Physiol 76: 2154-2156, 1994.
24. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 81: 483-487, 1999.
25. Nagaya N, Goto Y, Satoh T, et al. Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction. J Cardiovasc Pharmacol 39: 754-760, 2002.
26. Cao J, Zhang J, Wang X. Changes and cardiac protective effects of adrenomedullin during myocardial ischemia-reperfusion period. Zhonghua Yi Xue Za Zhi 80: 261-264, 2000.
27. Niu P, Shindo T, Iwata H, et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 109: 1789-1794, 2004.
28. Kawai J, Ando K, Tojo A, et al Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 109 1147-1153, 2004.
29. Okumura H, Nagaya N, Kangawa K, et al. Adrenomedullin infusion during ischemia/reperfusion attenuates left ventricular remodeling and myocardial fibrosis in rats. Hypertens Res 26: S99-S104, 2004.
30. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109 242-248, 2004.